Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590588 | 1.00 | SLC6A2 (0.40) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818305 | 0.89 | SLC6A2 (0.42) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818308 | 0.89 | SLC6A2 (0.42) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818317 | 0.85 | SLC6A2 (0.45) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818315 | 0.85 | SLC6A2 (0.45) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818348 | 0.85 | — | — | |
| SCHEMBL17818250 | 0.85 | — | — | |
| SCHEMBL17818349 | 0.85 | — | — | |
| SCHEMBL21456786 | 0.85 | — | — | |
| SCHEMBL17818249 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029994-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20180030004-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9815804-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9549916-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-9549916-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | SLC6A2 3540/4885MMP12 122/4885MMP13 881/4885 |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | SLC6A2 3540/4885MMP12 122/4885MMP13 881/4885 |
| US-20180030004-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | LCT, AGXT, LPXN | SLC6A2 3540/4885MMP12 122/4885MMP13 881/4885 |
| US-10029994-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | LCT, AGXT, LPXN | SLC6A2 3540/4885MMP12 122/4885MMP13 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.